Literature DB >> 9420032

Antimicrobial susceptibility testing of 230 Helicobacter pylori strains: importance of medium, inoculum, and incubation time.

S H Hartzen1, L P Andersen, A Bremmelgaard, H Colding, M Arpi, J Kristiansen, T Justesen, F Espersen, N Frimodt-Møller, O Bonnevie.   

Abstract

No standardized method of susceptibility testing for Helicobacter pylori is currently available, so before a large agar dilution study comprising 230 H. pylori strains belonging to more than 80 genetically different groups was initiated, we performed a relatively small preliminary study to determine the influences of medium, inoculum density, and incubation time. Seven media were investigated and were primarily evaluated on the basis of their abilities to support growth both semiquantitatively and qualitatively; Iso-Sensitest agar supplemented with 10% horse blood was found to be well suited for the purpose; this was closely followed by Mueller-Hinton agar with 10% horse blood, Mueller-Hinton with 10% sheep blood, and finally, 7% lysed horse blood agar. Investigations of two inoculum densities and two incubation times resulted in recommendations for the use of 10(9) CFU/ml (10[6] CFU/spot) as the inoculum and 72 h as the incubation time. A modest inoculum effect was noted for amoxicillin and metronidazole. By the methodology derived from our preliminary study, the susceptibilities of 230 H. pylori strains to six antibiotics were subsequently determined. The results were generally in accord with those of others, and apart from metronidazole, the MIC of which for approximately 25% of the strains tested was >8 microg/ml, resistance was low in Denmark. The situation might, however, quickly change when and if the number of indications for antibiotic therapy for H. pylori infections increase. Consequently, susceptibility testing of all H. pylori strains is recommended in order to survey the development of resistance, and in our hands the described methodology was relatively easy to perform and the results were easy to read.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9420032      PMCID: PMC164182     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  17 in total

1.  Clarithromycin resistance in Helicobacter pylori: prevalence in untreated dyspeptic patients and stability in vitro.

Authors:  H X Xia; M Buckley; C T Keane; C A O'Morain
Journal:  J Antimicrob Chemother       Date:  1996-03       Impact factor: 5.790

2.  Comparative in vitro activities of six new fluoroquinolones and other oral antimicrobial agents against Campylobacter pylori.

Authors:  A E Simor; S Ferro; D E Low
Journal:  Antimicrob Agents Chemother       Date:  1989-01       Impact factor: 5.191

3.  Susceptibility of Campylobacter pyloridis to 20 antimicrobial agents.

Authors:  T Lambert; F Mégraud; G Gerbaud; P Courvalin
Journal:  Antimicrob Agents Chemother       Date:  1986-09       Impact factor: 5.191

4.  Comparison of a selective and a non-selective medium in the diagnosis of gonorrhoea to ascertain the sensitivity of Neisseria gonorrhoeae to vancomycin.

Authors:  A Reyn; M W Bentzon
Journal:  Br J Vener Dis       Date:  1972-10

5.  In vitro susceptibility of Campylobacter pyloridis to cimetidine, sucralfate, bismuth and sixteen antibiotics.

Authors:  J J Andreasen; L P Andersen
Journal:  Acta Pathol Microbiol Immunol Scand B       Date:  1987-04

6.  Susceptibility of Campylobacter pyloridis to three macrolide antibiotics (erythromycin, roxithromycin [RU 28965], and CP 62,993) and rifampin.

Authors:  S Czinn; H Carr; S Aronoff
Journal:  Antimicrob Agents Chemother       Date:  1986-08       Impact factor: 5.191

7.  Susceptibility of clinical isolates of Campylobacter pylori to twenty-one antimicrobial agents.

Authors:  C A McNulty; J C Dent
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-08       Impact factor: 3.267

8.  Susceptibility of Campylobacter pylori to the newer cephalosporin antibiotics.

Authors:  S J Czinn; H Carr; V Hupertz
Journal:  Chemotherapy       Date:  1989       Impact factor: 2.544

9.  Susceptibility of clinical isolates of Campylobacter pylori to 24 antimicrobial and anti-ulcer agents.

Authors:  Y Glupczynski; M Delmee; C Bruck; M Labbe; V Avesani; A Burette
Journal:  Eur J Epidemiol       Date:  1988-06       Impact factor: 8.082

10.  Susceptibility of Campylobacter pylori to macrolides and fluoroquinolones.

Authors:  D J Hardy; C W Hanson; D M Hensey; J M Beyer; P B Fernandes
Journal:  J Antimicrob Chemother       Date:  1988-11       Impact factor: 5.790

View more
  12 in total

1.  In vitro activities of a new ketolide, ABT-773, alone and in combination with amoxicillin, metronidazole, or tetracycline against Helicobacter pylori.

Authors:  S L Pendland; J L Prause; M M Neuhauser; N Boyea; J M Hackleman; L H Danziger
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

2.  In vitro anti-Helicobacter pylori activities of new rifamycin derivatives, KRM-1648 and KRM-1657.

Authors:  J K Akada; M Shirai; K Fujii; K Okita; T Nakazawa
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

3.  Problems related to determination of MICs of oximino-type expanded-spectrum cephems for Proteus vulgaris.

Authors:  A Ohno; Y Ishii; L Ma; K Yamaguchi
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

4.  Antimicrobial susceptibility testing of Helicobacter pylori in a large multicenter trial: the MACH 2 study.

Authors:  F Mégraud; N Lehn; T Lind; E Bayerdörffer; C O'Morain; R Spiller; P Unge; S V van Zanten; M Wrangstadh; C F Burman
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

5.  Evaluation of a selective transport medium for gastric biopsy specimens to be cultured for Helicobacter pylori.

Authors:  L K Siu; W K Leung; A F Cheng; J Y Sung; T K Ling; J M Ling; E K Ng; J Y Lau; S C Chung
Journal:  J Clin Microbiol       Date:  1998-10       Impact factor: 5.948

6.  Effects of metronidazole, tetracycline, and bismuth-metronidazole-tetracycline triple therapy in the Helicobacter pylori SS1 mouse model after 1 day of dosing: development of an H. pylori lead selection model.

Authors:  Christine F Sizemore; Joel D Quispe; Karen M Amsler; Todd C Modzelewski; Jayson J Merrill; D Andrew Stevenson; Lorie A Foster; Andrew M Slee
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

7.  In vitro antimicrobial susceptibility testing of Helicobacter felis, H. bizzozeronii, and H. salomonis.

Authors:  K Van den Bulck; A Decostere; I Gruntar; M Baele; B Krt; R Ducatelle; F Haesebrouck
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

8.  Assessment of metronidazole susceptibility in Helicobacter pylori: statistical validation and error rate analysis of breakpoints determined by the disk diffusion test.

Authors:  S Chaves; M Gadanho; R Tenreiro; J Cabrita
Journal:  J Clin Microbiol       Date:  1999-05       Impact factor: 5.948

9.  Multilaboratory comparison of proficiencies in susceptibility testing of Helicobacter pylori and correlation between agar dilution and E test methods.

Authors:  L M Best; D J M Haldane; M Keelan; D E Taylor; A B R Thomson; V Loo; C A Fallone; P Lyn; F M Smaill; R Hunt; C Gaudreau; J Kennedy; M Alfa; R Pelletier; S J O Veldhuyzen Van Zanten
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

10.  Inhibition of nanobacteria by antimicrobial drugs as measured by a modified microdilution method.

Authors:  N Cíftçíoglu; M A Miller-Hjelle; J T Hjelle; E O Kajander
Journal:  Antimicrob Agents Chemother       Date:  2002-07       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.